This Article Full Text Full Text (PDF) Purchase Article View Shopping Cart Alert me when this article is cited Alert me if a correction is posted Services Email this article to a colleague Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Save to my personal folders Download to citation manager Rights & Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Masci, G. Articles by Santoro, A. Search for Related Content PubMed PubMed Citation Articles by Masci, G. Articles by Santoro, A. Social Bookmarking                            What's this?

Minidose Warfarin Prophylaxis for Catheter-Associated Thrombosis in Cancer Patients: Can It Be Safely Associated With Fluorouracil-Based Chemotherapy?

From the Departments of Medical Oncology and Hematology and Interventional Radiology, Istituto Clinico Humanitas, Rozzano, Milan, Italy.

Address reprint requests to Giovanna Masci, MD, Department of Medical Oncology and Hematology, Istituto Clinico Humanitas, Via Manzoni 56, 20089, Rozzano, Milano, Italy; email: giovanna.masci{at}humanitas.it.

Purpose: The use of prophylactic low-dose oral warfarin in cancer patients with a central venous catheter (CVC) in place has an established role in the prevention of thrombotic complications and is associated with a low hemorrhagic risk. Despite the literature indicating an adverse interaction between warfarin and fluorouracil (FU), the frequency of this interaction and whether it occurs when minidose warfarin is used is unknown. We analyzed the incidence of alterations in the International Normalized Ratio (INR) and bleeding in cancer patients given minidose warfarin during treatment with continuous-infusion FU-based regimens.

Patients and Methods: Between July 1999 and August 2001, 95 cancer patients were evaluated. Forty-one patients (43%) had liver metastases. Seventy-nine patients (83%) had a Groshong CVC (Bard Access System, Salt Lake City, UT), and 16 (17%) had a Port-a-Cath device (Bard Access System). All patients received oral warfarin at a dose of 1 mg/daily as prophylaxis beginning the day after the catheter was positioned. An INR of more than 1.5 was considered significantly elevated.

Results: INR elevation occurred in 31 patients (33%), with 18 patients (19%) having an INR more than 3.0. Twelve (39%) of the 31 patients had liver metastases. Bleeding was observed in eight patients (8%); seven of these patients had elevated INR levels. We observed INR elevations in 12 of 21 patients treated with a FU, folinic acid, and oxaliplatin (FOLFOX) regimen, 11 of 40 treated with a de Gramont regimen (FU and folinic acid), and five of 19 treated with a FU, folinic acid, and irinotecan (FOLFIRI) regimen.

Conclusion: A high incidence of INR abnormalities was observed in our cohort of patients, especially those treated with FOLFOX regimen. Clinicians should be aware of this interaction and should regularly monitor the prothrombin time in patients receiving warfarin and FU.

CiteULike    Complore    Connotea    Del.icio.us    Digg    Facebook    Reddit    Technorati    Twitter    What's this?

This article has been cited by other articles:

				A. A. Khorana Cancer and thrombosis: implications of published guidelines for clinical practice Ann. Onc., October 1, 2009; 20(10): 1619 - 1630. [Abstract] [Full Text] [PDF]

				P. Debourdeau, D. Kassab Chahmi, G. Le Gal, I. Kriegel, E. Desruennes, M.-C. Douard, I. Elalamy, G. Meyer, P. Mismetti, M. Pavic, et al. 2008 SOR guidelines for the prevention and treatment of thrombosis associated with central venous catheters in patients with cancer: report from the working group Ann. Onc., September 1, 2009; 20(9): 1459 - 1471. [Abstract] [Full Text] [PDF]

				M. De Cicco, M. Matovic, L. Balestreri, A. Steffan, R. Pacenzia, M. Malafronte, D. Fantin, C. A. Bertuzzi, F. Fabiani, S. Morassut, et al. Early and short-term acenocumarine or dalteparin for the prevention of central vein catheter-related thrombosis in cancer patients: a randomized controlled study based on serial venographies Ann. Onc., June 30, 2009; (2009) mdp235v1. [Abstract] [Full Text] [PDF]

				W. H. Geerts, D. Bergqvist, G. F. Pineo, J. A. Heit, C. M. Samama, M. R. Lassen, and C. W. Colwell Prevention of Venous Thromboembolism: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition) Chest, June 1, 2008; 133(6_suppl): 381S - 453S. [Abstract] [Full Text] [PDF]

				A. Chan, A. Iannucci, and W. E Dager Systemic Anticoagulant Prophylaxis for Central Catheter-Associated Venous Thrombosis in Cancer Patients Ann. Pharmacother., April 1, 2007; 41(4): 635 - 641. [Abstract] [Full Text] [PDF]

				M. Magagnoli, G. Masci, L. Castagna, E. Morenghi, and A. Santoro High incidence of INR alteration in gastrointestinal cancer patients treated with mini-dose warfarin and 5-fluorouracil-based regimens Ann. Onc., January 1, 2006; 17(1): 174 - 176. [Full Text] [PDF]

				G. Giunta Warfarin-5-FU interactions Ann. Onc., January 1, 2006; 17(1): 176 - 176. [Full Text] [PDF]

				R. Camidge, B. Reigner, J. Cassidy, S. Grange, M. Abt, E. Weidekamm, and D. Jodrell Significant Effect of Capecitabine on the Pharmacokinetics and Pharmacodynamics of Warfarin in Patients With Cancer J. Clin. Oncol., July 20, 2005; 23(21): 4719 - 4725. [Abstract] [Full Text] [PDF]

				M. Levine and A.K. Kakkar Catheter-Associated Thrombosis: Thromboprophylaxis or Not? J. Clin. Oncol., June 20, 2005; 23(18): 4006 - 4008. [Full Text] [PDF]

				L. R. Zacharski, P. Prandoni, and M. Monreal Warfarin Versus Low-Molecular-Weight Heparin Therapy in Cancer Patients Oncologist, January 1, 2005; 10(1): 72 - 79. [Abstract] [Full Text] [PDF]

				M. Magagnoli, L. Castagna, G. Masci, and A. Santoro Low-Dose Warfarin Prophylaxis for Catheter-Associated Thrombosis in Cancer Patients. Can It Be Safely Associated with 5-Fluorouracil-Based Chemotherapy? Oncologist, September 1, 2004; 9(5): 594 - 595. [Full Text] [PDF]

				W. H. Geerts, G. F. Pineo, J. A. Heit, D. Bergqvist, M. R. Lassen, C. W. Colwell, and J. G. Ray Prevention of Venous Thromboembolism: The Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy Chest, September 1, 2004; 126(3_suppl): 338S - 400S. [Abstract] [Full Text] [PDF]

				M. Mandala, G. Curigliano, P. Bucciarelli, G. Ferretti, P. M. Mannucci, M. Colleoni, A. Ventura, G. Peruzzotti, G. Severi, P. G. Pelicci, et al. Factor V Leiden and G20210A prothrombin mutation and the risk of subclavian vein thrombosis in patients with breast cancer and a central venous catheter Ann. Onc., April 1, 2004; 15(4): 590 - 593. [Abstract] [Full Text] [PDF]

				J. A. Lopez, C. Kearon, and A. Y.Y. Lee Deep Venous Thrombosis Hematology, January 1, 2004; 2004(1): 439 - 456. [Abstract] [Full Text] [PDF]

				M. Magagnoli, G. Masci, C. Carnaghi, P. A. Zucali, L. Castagna, E. Morenghi, and A. Santoro Minidose warfarin is associated with a high incidence of International Normalized Ratio elevation during chemotherapy with FOLFOX regimen Ann. Onc., June 1, 2003; 14(6): 959 - 960. [Full Text] [PDF]